370 related articles for article (PubMed ID: 19408340)
1. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
Afif W; Leighton JA; Hanauer SB; Loftus EV; Faubion WA; Pardi DS; Tremaine WJ; Kane SV; Bruining DH; Cohen RD; Rubin DT; Hanson KA; Sandborn WJ
Inflamm Bowel Dis; 2009 Sep; 15(9):1302-7. PubMed ID: 19408340
[TBL] [Abstract][Full Text] [Related]
2. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
[TBL] [Abstract][Full Text] [Related]
3. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
Baert F; Vande Casteele N; Tops S; Noman M; Van Assche G; Rutgeerts P; Gils A; Vermeire S; Ferrante M
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1324-32. PubMed ID: 25277873
[TBL] [Abstract][Full Text] [Related]
4. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis.
Wolf D; D'Haens G; Sandborn WJ; Colombel JF; Van Assche G; Robinson AM; Lazar A; Zhou Q; Petersson J; Thakkar RB
Aliment Pharmacol Ther; 2014 Sep; 40(5):486-97. PubMed ID: 25041859
[TBL] [Abstract][Full Text] [Related]
5. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.
Triantafillidis JK; Mantzaris G; Karagiannis J; Papavasilliou E; Papatheodoridis G; Fouskas J; Malgarinos G; Gikas A; Papamichael K; Mathou N; Symboulakis E; Karamanolis D
Rev Med Chir Soc Med Nat Iasi; 2010; 114(1):85-90. PubMed ID: 20509281
[TBL] [Abstract][Full Text] [Related]
6. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants.
Reinisch W; Sandborn WJ; Panaccione R; Huang B; Pollack PF; Lazar A; Thakkar RB
Inflamm Bowel Dis; 2013 Jul; 19(8):1700-9. PubMed ID: 23665965
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.
Peyrin-Biroulet L; Laclotte C; Roblin X; Bigard MA
World J Gastroenterol; 2007 Apr; 13(16):2328-32. PubMed ID: 17511032
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience.
Oussalah A; Laclotte C; Chevaux JB; Bensenane M; Babouri A; Serre AA; Boucekkine T; Roblin X; Bigard MA; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2008 Oct; 28(8):966-72. PubMed ID: 18652603
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice.
Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Rutka M; Molnár T
J Crohns Colitis; 2016 Jan; 10(1):26-30. PubMed ID: 26392413
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
[TBL] [Abstract][Full Text] [Related]
11. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
12. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome.
García-Bosch O; Gisbert JP; Cañas-Ventura A; Merino O; Cabriada JL; García-Sánchez V; Gutiérrez A; Nos P; Peñalva M; Hinojosa J; García-Planella E; Muñoz F; Calvet X; Panés J
J Crohns Colitis; 2013 Oct; 7(9):717-22. PubMed ID: 23142005
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.
Taxonera C; Estellés J; Fernández-Blanco I; Merino O; Marín-Jiménez I; Barreiro-de Acosta M; Saro C; García-Sánchez V; Gento E; Bastida G; Gisbert JP; Vera I; Martinez-Montiel P; Garcia-Morán S; Sánchez MC; Mendoza JL
Aliment Pharmacol Ther; 2011 Feb; 33(3):340-8. PubMed ID: 21133961
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
Thorlund K; Druyts E; Toor K; Mills EJ
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
Suzuki Y; Motoya S; Hanai H; Matsumoto T; Hibi T; Robinson AM; Mostafa NM; Chao J; Arora V; Camez A; Thakkar RB; Watanabe M
J Gastroenterol; 2014 Feb; 49(2):283-94. PubMed ID: 24363029
[TBL] [Abstract][Full Text] [Related]
18. Short-term response to adalimumab in childhood inflammatory bowel disease.
Noe JD; Pfefferkorn M
Inflamm Bowel Dis; 2008 Dec; 14(12):1683-7. PubMed ID: 18618629
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis.
Fernández-Blanco JI; Fernández-Díaz G; Cara C; Vera MI; Olivares D; Taxonera C
Dig Dis Sci; 2018 Mar; 63(3):731-737. PubMed ID: 29372480
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
Peyrin-Biroulet L; Laclotte C; Bigard MA
Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
